ppt课件-coremodulesformsoftobacco-rxforchangehome.pptVIP

While the use of first- and second-line medications approximately double the likelihood that a patient will successfully quit smoking, data from clinical trials suggest that only 19–33% of patients remain abstinent six months after quitting (Fiore et al, 2008). Given these low success rates, clinicians and researchers have explored modified approaches to standard therapies, including the use of combination therapy. Data from randomized, controlled trials suggest that certain combinations of first-line cessation medications are efficacious in promoting long-term abstinence and the 2008 Clinical Practice Guideline recommends that clinicians consider the use of combination therapy as a first-line treatment approach for patients during a quit attempt (Fiore et al., 2008). Plasma levels of nicotine achieved with standard doses of NRT are generally much lower than those attained with regular smoking. As such, conventionally dosed NRT may deliver sub-therapeutic nicotine levels for some individuals, and in particular, for moderate-to-heavy smokers. Dual NRT regimens, which typically consist of a long-acting agent (e.g., nicotine patch) in combination with a short-acting formulation (i.e., gum, lozenge, inhaler, or nasal spray) are being increasingly used as initial therapy. The long-acting formulation, which delivers nicotine at relatively constant level, is used to prevent the onset of severe withdrawal symptoms while the short-acting formulation, which delivers nicotine at a more rapid rate, is used as needed to control withdrawal symptoms that may occur during potential relapse situations (e.g., after meals, during times of stress, when around other smokers). Evidence suggests that patients who use combination NRT are 1.3 times as likely to remain abstinent when compared with patients who use single-agent NRT (Stead et al., 2012). Similarly, quit rates with combination therapy that included NRT (gum, patch, lozenge) and bupropion SR were 1.2 times those attained w